KAHR
Jerusalem, Israel · Founded 2005
- Headquarters
- Jerusalem
- Employees
- 11–50
- Founded
- 2005
- Business Model
- B2B
- Website
- kahrmedical.com
- Last Round
- Series AFeb 2020
- Rounds
- 2
About
KAHR Medical is a clinical-stage Israeli biotechnology company that develops proprietary bispecific fusion protein therapeutics designed to modulate immune checkpoints for the treatment of cancer and autoimmune diseases. Founded in 2005 and headquartered in Jerusalem, the company's pipeline includes first-in-class T-cell engagers aimed at transforming immunotherapy for indications such as microsatellite-stable colorectal cancer. KAHR Medical has raised funding across multiple rounds, including Series B financing, to advance its immunotherapeutics platform toward clinical development.
Summary
KAHR is a Biotech company based in Jerusalem, Israel, founded in 2005. Its most recent funding was a Series A round in Feb 2020. Investors include Oriella Limited, Pavilion Capital and Mirae Asset Venture Investment.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.